These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
119 related articles for article (PubMed ID: 22304574)
1. Tag SNPs of the ancestral haplotype 57.1 do not substitute HLA-B*57:01 typing for eligibility to abacavir treatment in the Italian population. Badulli C; Sestini R; Sbarsi I; Baroncelli M; Pizzochero C; Martinetti M; Porfirio B Pharmacogenomics; 2012 Feb; 13(3):247-9. PubMed ID: 22304574 [No Abstract] [Full Text] [Related]
2. In Mexican Mestizos the HCP5 rs2395029 SNP may be a genetic marker for screening abacavir hypersensitivity. Sanchez-Giron F; Carnevale A Pharmacogenomics; 2012 Feb; 13(3):251-2. PubMed ID: 22304575 [No Abstract] [Full Text] [Related]
3. Association of the genetic marker for abacavir hypersensitivity HLA-B*5701 with HCP5 rs2395029 in Mexican Mestizos. Sanchez-Giron F; Villegas-Torres B; Jaramillo-Villafuerte K; Silva-Zolezzi I; Fernandez-Lopez JC; Jimenez-Sanchez G; Carnevale A Pharmacogenomics; 2011 Jun; 12(6):809-14. PubMed ID: 21510768 [TBL] [Abstract][Full Text] [Related]
4. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Mallal S; Nolan D; Witt C; Masel G; Martin AM; Moore C; Sayer D; Castley A; Mamotte C; Maxwell D; James I; Christiansen FT Lancet; 2002 Mar; 359(9308):727-32. PubMed ID: 11888582 [TBL] [Abstract][Full Text] [Related]
5. Abacavir hypersensitivity. Vandekerckhove L; Blot S; Vogelaers D N Engl J Med; 2008 Jun; 358(23):2514-5; author reply 2515-6. PubMed ID: 18525052 [No Abstract] [Full Text] [Related]
7. Prospective HLA-B*5701 screening and abacavir hypersensitivity: a single centre experience. Waters LJ; Mandalia S; Gazzard B; Nelson M AIDS; 2007 Nov; 21(18):2533-4. PubMed ID: 18025891 [TBL] [Abstract][Full Text] [Related]
8. Pharmacogenomics testing for type B adverse drug reactions to anti-infective drugs: the example of hypersensitivity to abacavir. Agundez JA; Esguevillas G; Amo G; Garcia-Martin E Recent Pat Antiinfect Drug Discov; 2014; 9(2):151. PubMed ID: 25891395 [No Abstract] [Full Text] [Related]
9. Abacavir hypersensitivity. Abel S; Paturel L; Cabié A N Engl J Med; 2008 Jun; 358(23):2515; author reply 2515-6. PubMed ID: 18536095 [No Abstract] [Full Text] [Related]
11. Current trends in screening across ethnicities for hypersensitivity to abacavir. Rodriguez-Nóvoa S; Soriano V Pharmacogenomics; 2008 Oct; 9(10):1531-41. PubMed ID: 18855539 [TBL] [Abstract][Full Text] [Related]
12. A simple screening approach to reduce B*5701-associated abacavir hypersensitivity on the basis of sequence variation in HIV reverse transcriptase. Chui CK; Brumme ZL; Brumme CJ; Yip B; Phillips EJ; Montaner JS; Harrigan PR Clin Infect Dis; 2007 Jun; 44(11):1503-8. PubMed ID: 17479950 [TBL] [Abstract][Full Text] [Related]
13. Labeling changes for abacavir. AIDS Patient Care STDS; 2008 Aug; 22(8):683-4. PubMed ID: 18721055 [No Abstract] [Full Text] [Related]
14. The convenience of flow cytometry for HLA-B*5701 screening to prevent abacavir hypersensitivity reactions. Airo P; Scarsi M; Malagoli A; Carella G; Izzo I; Carosi G; Torti C J Acquir Immune Defic Syndr; 2009 Jul; 51(3):361-2. PubMed ID: 19553774 [No Abstract] [Full Text] [Related]
15. Genetic association studies to detect adverse drug reactions: abacavir hypersensitivity as an example. Hughes AR; Brothers CH; Mosteller M; Spreen WR; Burns DK Pharmacogenomics; 2009 Feb; 10(2):225-33. PubMed ID: 19207023 [TBL] [Abstract][Full Text] [Related]
16. HLA-B*5701 Genotyping for Abacavir Prescription: Re-Examination of its Cost-Effectiveness in Singapore. Goh KS; Kapoor R; Lee CC; Ng CY; Leong KP Ann Acad Med Singap; 2019 Apr; 48(4):133-138. PubMed ID: 31131386 [No Abstract] [Full Text] [Related]